Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process
about
Regulation of Bim in Health and DiseaseBcl-2 antagonists: a proof of concept for CLL therapyConcise review: Leukemia stem cells in personalized medicineUpdate on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunitiesRational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML.Implementation of validated pharmacodynamic assays in multiple laboratories: challenges, successes, and limitations.PI3K/mTOR inhibition markedly potentiates HDAC inhibitor activity in NHL cells through BIM- and MCL-1-dependent mechanisms in vitro and in vivo.A multicenter phase I/II study of obatoclax mesylate administered as a 3- or 24-hour infusion in older patients with previously untreated acute myeloid leukemia.Molecular interactions of prodiginines with the BH3 domain of anti-apoptotic Bcl-2 family membersMultiple mechanisms mediate resistance to sorafenib in urothelial cancerNew strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.The BCL2-938 C > A promoter polymorphism is associated with risk group classification in children with acute lymphoblastic leukemia.Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.Sparse expression bases in cancer reveal tumor drivers.Tailored fragments of roseophilin selectively antagonize Mcl-1 in vitroRational Combinations of Targeted Agents in AMLBCL-2 Antagonism to Target the Intrinsic Mitochondrial Pathway of Apoptosis.The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 statusGrowth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinomaProteolytic systems and AMP-activated protein kinase are critical targets of acute myeloid leukemia therapeutic approaches.MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid MalignanciesAn evidence-based review of obatoclax mesylate in the treatment of hematological malignanciesCXCR4 chemokine receptor signaling induces apoptosis in acute myeloid leukemia cells via regulation of the Bcl-2 family members Bcl-XL, Noxa, and BakMcl-1 as a Therapeutic Target in Acute Myelogenous Leukemia (AML).High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cellsMetabolomics profiles delineate uridine deficiency contributes to mitochondria-mediated apoptosis induced by celastrol in human acute promyelocytic leukemia cells.Obatoclax, a Pan-BCL-2 Inhibitor, Targets Cyclin D1 for Degradation to Induce Antiproliferation in Human Colorectal Carcinoma Cells.Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancerRole of the Crosstalk between Autophagy and Apoptosis in CancerAutophagy in blood cancers: biological role and therapeutic implications.The Bcl-2/Bax and Ras/Raf/MEK/ERK signaling pathways: implications in pediatric leukemia pathogenesis and new prospects for therapeutic approaches.Cytokine Signaling in Tumor Progression.Degradation of Keap1 activates BH3-only proteins Bim and PUMA during hepatocyte lipoapoptosisAzacytidine and erlotinib exert synergistic effects against acute myeloid leukemia.BH3 mimetic Obatoclax (GX15-070) mediates mitochondrial stress predominantly via MCL-1 inhibition and induces autophagy-dependent necroptosis in human oral cancer cells.The genetically engineered drug rhCNB induces apoptosis via a mitochondrial route in tumor cellsArsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.Low probability activation of Bax/Bak can induce selective killing of cancer cells by generating heterogeneity in apoptosis.The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression.Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma.
P2860
Q26781203-872ECA5D-CDFF-45B4-8E19-98B09B8E0482Q26823996-221EA1BF-4508-4AAD-9ABD-9953818EEC7CQ26995268-904944BC-79E1-455F-880C-00738198AAEEQ28071384-2F56AD08-EA1A-4E54-BD68-A9A68311A598Q33840360-047F2748-0354-403D-AC11-C96CD9423F9FQ33897223-4F946ED3-4611-4E04-8249-760368256888Q34199935-24589D98-C645-41CC-9690-30BFDA3A789BQ34294097-1798EE47-7DAD-49AA-A66B-56D382D991D8Q34608671-44A2D057-16E6-4C37-81C4-92910E661E49Q34685436-8BDE71AA-AB76-4D98-9FB7-9C72B8648B87Q34715598-36E7BC22-865E-4220-9BBF-2713B2B74643Q35006917-A645572B-F97B-4050-A363-35D70EE289F6Q35007971-4014AEBF-E9CE-4B75-973B-064B43482CB5Q35088941-94152A57-21D3-42EF-99F5-92A6F5D77BCBQ35639894-CCEFB93F-2516-47AA-9A66-7DCB59C77390Q35750491-14E4008E-273B-471C-B0DC-3F3B1023F618Q36284637-09518249-5C6A-4416-9BC8-AA1D946DB02BQ36366626-4F11A77B-A705-4BC7-A907-0F4086937ADFQ36413954-384114F3-CC94-4766-8E98-062725450599Q36544596-C42FFC79-C76F-46A5-B62C-5AF482E13CEFQ36602853-ECFF17F8-82FB-4290-B754-D0D2EF6833DDQ36696524-74EC0315-D582-4C06-A984-E64409CDD4B3Q37095358-D1099A7A-B543-434C-B2F9-4F4ED921EC7FQ37104378-1E74DBFE-7C00-491C-8E12-80199E214F3EQ37209768-04557AA6-2386-43C2-BE6E-1EA81C161EEEQ37564804-D6E40E5D-C425-4A07-893C-02EAE845AF3AQ37631444-07589458-C825-4543-81F8-124C7A093DA1Q37715399-96DB6392-EEE5-4021-8287-16DBD4395D0BQ38120523-8E878348-FFA8-4465-B4C8-5A3057A4B63EQ38134372-1918F152-D21F-4CA1-9CF0-128D0C8EA8A6Q38148218-6C5AC102-B120-433A-91DB-8C8164F058E4Q38598868-E0EE8625-2873-4A93-B225-B97712F952B4Q39000961-4178B332-6B5F-454A-8C2E-9069BB1FFE29Q39255686-3CBA319A-DC20-42AD-A6C4-F2DC49C6BB9AQ41694352-9EED6A32-D875-4C75-953F-DC995E082F9EQ42371592-81E597E5-E21D-43E7-BCD2-25C2FDF2FBE0Q42703579-78A2E587-EF9A-4900-9777-3C51BAB945ABQ44357715-D10FDF48-5314-4D84-9DC6-6B6EAD876F5DQ45865484-0365C84B-A631-4338-A0E1-581C1270F294Q52571263-7994F37B-1D8D-4B60-984C-E93034BCEDB5
P2860
Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Inhibition of Bcl-2 antiapopto ...... hrough a Bim-dependent process
@ast
Inhibition of Bcl-2 antiapopto ...... hrough a Bim-dependent process
@en
type
label
Inhibition of Bcl-2 antiapopto ...... hrough a Bim-dependent process
@ast
Inhibition of Bcl-2 antiapopto ...... hrough a Bim-dependent process
@en
prefLabel
Inhibition of Bcl-2 antiapopto ...... hrough a Bim-dependent process
@ast
Inhibition of Bcl-2 antiapopto ...... hrough a Bim-dependent process
@en
P2093
P2860
P1433
P1476
Inhibition of Bcl-2 antiapopto ...... hrough a Bim-dependent process
@en
P2093
Andrea Ferreira-Gonzalez
David C Williams
Elisa Attkisson
Mandy Mayo Aust
Steven Grant
P2860
P304
P356
10.1182/BLOOD-2011-09-378141
P407
P577
2012-03-23T00:00:00Z